Market Overview

7 Biggest Price Target Changes For Wednesday

  • Credit Suisse raised the price target for, inc. (NYSE: CRM) from $150 to $155. shares closed at $126.88 on Tuesday.
  • Morgan Stanley boosted the price target for WellCare Health Plans, Inc. (NYSE: WCG) from $228 to $237. WellCare Health shares closed at $221.15 on Tuesday.
  • Barclays increased Palo Alto Networks, Inc. (NYSE: PANW) price target from $206 to $235. Palo Alto shares closed at $207.85 on Tuesday.
  • Baird boosted Ulta Beauty, Inc. (NASDAQ: ULTA) price target from $265 to $290. Ulta Beauty shares closed at $253.69 on Tuesday.
  • SunTrust Robinson Humphrey cut DXC Technology Company (NYSE: DXC) price target from $115 to $105. DXC Technology shares closed at $89.99 on Tuesday.
  • Argus raised the price target on Costco Wholesale Corporation (NASDAQ: COST) from $200 to $220. Costco shares closed at $196.74 on Tuesday.
  • Credit Suisse lowered the price target for AbbVie Inc. (NYSE: ABBV) from $104 to $89. AbbVie shares closed at $99.47 on Tuesday.

Posted-In: Price Target ChangesPrice Target Intraday Update Analyst Ratings


Related Articles (COST + ABBV)

View Comments and Join the Discussion!

Latest Ratings

CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Italy ETF Walloped As 'Quitaly' Speculation Intensifies

Morgan Stanley: What To Like In Salesforce's Q1